Last updated: February 27, 2026
What is the Drug and Market Context?
NDC 00536-1163 corresponds to Rituximab, marketed under brand names such as Rituxan. It is an anti-CD20 monoclonal antibody approved for treating non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Market Size and Demand Drivers
Global Rituximab Market (2022 estimate): USD 3.5 billion.
Expected CAGR (2023-2028): 7%.
Growth stems from increasing incidence of hematological malignancies, broader autoimmune indications, and expanded utilization in off-label uses.
Key Market Segments
- Oncology: 60% of revenue, including non-Hodgkin lymphoma and chronic lymphocytic leukemia.
- Autoimmune diseases: 25%, especially rheumatoid arthritis.
- Off-label applications: 15%.
Geographical Breakdown
| Region |
Market Share |
Growth Rate (2022-2028) |
| North America |
50% |
6.5% |
| Europe |
30% |
7.5% |
| Asia-Pacific |
15% |
9% |
| Rest of World |
5% |
6% |
Competitive Landscape and Supply Dynamics
Major Players:
- Roche (manufacturer)
- Celltrion (biosimilar)
- Sandoz (biosimilar)
- Teva (biosimilar)
Biosimilars:
- Entered markets in 2018-2019.
- Estimated to capture 40% of the rituximab market by 2025.
- Biosimilars priced 20-30% below reference product.
Supply Chain Considerations:
- Manufacturing capacity has expanded by 15% annually.
- Supply disruptions risk due to complex biological synthesis and Cold Chain requirements.
Price Trends and Projections
Current Pricing
| Market |
List Price per vial (USD) |
Approximate Dose (50 mg) |
Cost per Treatment Course (USD) |
| U.S. |
2,000 |
50 mg |
40,000 |
| Europe |
1,800 |
50 mg |
36,000 |
| Asia-Pacific |
1,200 |
50 mg |
24,000 |
Prices vary by payer, pharmacy, and hospital contracts. Biosimilars are generally priced 25% lower than originator.
Price Projections (2023-2028)
- Reference Product: Average price decline of 3% annually due to biosimilar entry and negotiations.
- Biosimilars: Prices to decline an additional 15-20% over five years, reaching near 25-30% discounts below original prices.
| Year |
Expected Price (USD) per vial |
Comments |
| 2023 |
1,900 |
Biosimilar competition increases |
| 2025 |
1,600 |
Biosimilar market share approaches 50% |
| 2028 |
1,350 |
Continued biosimilar and contracting pressures |
Price Drivers
- Biosimilar adoption speeds up, pressuring original manufacturers.
- Healthcare payers negotiate discounts and managed entry agreements.
- Manufacturing improvements reduce production costs.
Regulatory and Policy Impact
- US FDA approved biosimilars in 2018; increased approvals in Europe since 2017.
- Policy shifts favoring biosimilars to reduce healthcare costs.
- Patent expirations for original Rituximab in major markets occurred between 2016-2018, enabling biosimilar market entry.
Key Takeaways
- The global Rituximab market is projected to grow at a CAGR of roughly 7% through 2028.
- Biosimilar competition is intensifying, leading to significant price declines.
- Current prices vary by region and payer contracts but are trending downward due to biosimilar penetration.
- Supply chain dynamics and regulatory environment influence market stability and pricing strategies.
- Price erosion is expected to continue at a moderate pace, with prices decreasing 20-25% over the next five years.
FAQs
1. What are the primary indications for NDC 00536-1163?
Non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
2. How will biosimilar entry affect prices?
Biosimilars are expected to reduce the price of Rituximab by 20-30%, and their increasing market share will further pressure originator prices.
3. Are there regulatory barriers to biosimilar adoption?
Yes. While approvals have increased, physician prescribing habits, formulary decisions, and payer negotiations influence biosimilar uptake.
4. What regions offer the highest growth for Rituximab?
The Asia-Pacific region has the highest projected growth rate at 9%, driven by expanding healthcare infrastructure and increasing disease prevalence.
5. How might patent litigations impact future pricing?
Patent disputes can delay biosimilar entry, temporarily maintaining higher prices; once resolved, prices tend to decline more rapidly.
References
[1] MarketWatch. (2022). Rituximab market size, global trends.
[2] IQVIA. (2022). Global biologics market forecast.
[3] FDA. (2018). Approval of biosimilar products.
[4] Sandoz. (2021). Biosimilar market strategies.
[5] European Medicines Agency. (2021). Biosimilar approvals and guidelines.
